Fairvalue-Calculator Fairvalue-Calculator
EN DE

SciVision Biotech Inc (1786) Fair Value & Analysis

Healthcare · TW · Market cap 4.2B TWD

Price53.30 TWD
Fair Value47.73 TWD
Upside-10.5%
Quality95/100
Evidence: High Range 25.61 TWD – 59.66 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

SciVision Biotech Inc (1786) currently trades at 53.30 TWD, while our model-based Fair Value estimate is 47.73 TWD — implying the stock looks roughly 10.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

SciVision Biotech Inc. develops and manufactures medical-grade hyaluronic acid products in Taiwan. The company offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. It also involved in international trade; wholesale of medical equipment and cosmetics; and provides management advisory services. SciVision Biotech Inc. was founded in 1990 and is based in Kaohsiung, Taiwan.

Open the full interactive analysis →

Similar stocks

Intuitive Surgical, Inc (ISRG) -62% EssilorLuxottica Société anonyme (ESLOF) -34% HOYA Corporation (HOCPY) -42% Medline Inc (MDLN) -15% Becton, Dickinson and Company (BDX) -22% Alcon Inc (ALC) -44%

Frequently asked questions

Is SciVision Biotech Inc (1786) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 47.73 TWD versus a price of 53.30 TWD — about −10% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 1786?
Our 21-model fair value for SciVision Biotech Inc is 47.73 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 53.30 TWD.
What is the quality score of 1786?
SciVision Biotech Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.